05:59 AM EST, 11/06/2026 (MT Newswires) -- (Updates throughout with Novartis' statement) Novartis (NOVN.SW) said testing found evidence of vector DNA integration in two children who had previously received its Zolgensma gene therapy for spinal muscular atrophy. In an emailed statement to MT Newswires on Friday, the Swiss drugmaker said it received nine reports of tumors in patients treated with the therapy since its first approval in 2019. Both patients with confirmed evidence of vector DNA integration have undergone treatment and remain under monitoring. Novartis said the potential risk of tumors associated with vector integration is included in Zolgensma's prescribing information, adding that it had notified health authorities in both cases and would continue working with them on next steps.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.